- AtomVie Global Radiopharma has partnered with Radiopharm Ventures to develop and manufacture 177Lu-BetaBart, a radioantibody targeting B7-H3 for cancer treatment.
- The Phase I/II clinical trial for 177Lu-BetaBart is expected to commence in mid-2025, utilising AtomVie’s manufacturing expertise.
AtomVie Global Radiopharma, a radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a partnership with Radiopharm Ventures (RV) to develop and manufacture 177Lu-BetaBart. This targeted radioantibody focuses on B7-H3, an immune checkpoint molecule prevalent in multiple solid tumours. The collaboration aims to leverage the strengths of both companies in addressing high unmet medical needs in cancer treatment.
The partnership was formed between RV, a joint venture that includes Radiopharm Theranostics and the MD Anderson Cancer Center (MDACC). 177Lu-BetaBart is noted as the first targeted radiopharmaceutical specifically aimed at the 4Ig subtype of B7-H3, which is commonly expressed in human tumours. The antibody has been engineered to have a shorter blood circulation time and reduced on-target off-tissue toxicity, enhancing its potential for clinical application.
AtomVie will play a crucial role in advancing 177Lu-BetaBart from the clinic to commercialization. The first therapeutic trial, Phase I/II, is expected to start in mid-2025 across multiple tumour types in the US. AtomVie’s new facility, set to open in early 2025, spans 72,300 square feet and is designed to support the growing global pipeline of radiopharmaceuticals.
“Our collaboration with AtomVie is a significant step forward in our mission to bring innovative radiopharmaceutical therapies to patients,” stated Riccardo Canevari, Managing Director & CEO of RAD. He expressed confidence in AtomVie’s manufacturing and distribution capabilities to guide the project through clinical stages and towards commercialisation.
Bruno Paquin, CEO of AtomVie, emphasised the company’s commitment to advancing innovative therapies. “We are thrilled to partner with RAD on such an important project. This partnership reinforces our commitment to transforming patients’ lives with high-quality radiopharmaceuticals,” he remarked, underlining the company’s dedication to expanding its capabilities in the industry.
Overview of outsourcing trends 
